Methotrexate Therapy Duration and Management

Introduction to Methotrexate Continuation

Methotrexate should be continued indefinitely in patients with a satisfactory response, as long as the disease remains controlled and the medication is well-tolerated, with regular monitoring for toxicity, as recommended by the American College of Rheumatology 1

Tapering should only be attempted after sustained remission for at least 12 months, not simply after achieving a satisfactory response, according to the American College of Rheumatology 1
Tapering should only occur in cases of sustained long-term remission with normal inflammatory markers, not just symptomatic improvement, as suggested by the European League Against Rheumatism 2 and the American College of Rheumatology 1
If glucocorticoids are being used concomitantly, they should be withdrawn first before considering methotrexate tapering, as recommended by the American College of Rheumatology 1

Reduce methotrexate dose by 1 mg every 4 weeks (or 2.5 mg every 10 weeks) once lower doses are reached, as suggested by the American College of Rheumatology 1
Alternatively, extend the dosing interval to every 2 weeks while maintaining the same dose, which shows similar relapse rates to dose reduction, according to the American College of Rheumatology 1
Taper slowly over 2-3 months rather than abrupt discontinuation to minimize flare risk, as recommended by the American College of Rheumatology 1

For psoriasis, some patients can be gradually tapered off treatment and restarted when disease recurs, though it is important to minimize cumulative dose while maintaining disease control, as suggested by the American Academy of Dermatology 3
For Crohn's disease, attempt to reduce methotrexate only after sustained complete remission with normal inflammatory markers for several months, according to the European Crohn’s and Colitis Organisation 2
For psoriatic arthritis, although methotrexate is commonly used as the primary agent, the evidence base is limited, and continuation decisions should be based on ongoing disease control, as recommended by the American Academy of Dermatology 4

Complete blood count, liver function tests, and renal function every 3-4 months for patients on stable doses, as recommended by the American College of Rheumatology 5
More frequent monitoring (every 1-2 months) after dose increases or if symptoms develop, according to the American College of Rheumatology 5
Liver biopsy consideration in high-risk patients (diabetes, obesity, abnormal liver function tests, excessive alcohol use) or after cumulative doses exceeding 3.5-4 grams, as suggested by the American Academy of Dermatology 4

Abrupt discontinuation carries a 30-50% relapse rate within 12 months, as reported by the American College of Rheumatology 1
If disease recurs during tapering, restart methotrexate at the previously effective dose immediately, as recommended by the American College of Rheumatology 1
Consider maintaining low-dose therapy (5-7.5 mg weekly) rather than complete discontinuation in patients with severe disease or poor prognostic features, according to the American College of Rheumatology 1